Northwestern Mutual Wealth Management
APLS

Northwestern Mutual Wealth Management’s Apellis Pharmaceuticals APLS Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,281
Closed -$414K – 4097
2026
Q1 		$414K Buy
10,281
+9,681
+1,614% +$209K ﹤0.01% 1633
2025
Q4 		$15.1K Sell
600
-1
-0.2% -$23 ﹤0.01% 2860
2025
Q3 		$13.6K Buy
601
+1
+0.2% +$23 ﹤0.01% 2807
2025
Q2 		$10.4K Sell
600
-6
-1% -$111 ﹤0.01% 2789
2025
Q1 		$13.3K Buy
606
+6
+1% +$166 ﹤0.01% 2641
2024
Q4 		$19.1K Hold
600
– – ﹤0.01% 2531
2024
Q3 		$17.3K Hold
600
– – ﹤0.01% 2511
2024
Q2 		$23K Hold
600
– – ﹤0.01% 2348
2024
Q1 		$35.3K Hold
600
– – ﹤0.01% 2215
2023
Q4 		$35.9K Buy
+600
New +$30.4K ﹤0.01% 2188
2023
Q2 		– Sell
-116
Closed -$7.65K – 3343
2023
Q1 		$7.65K Buy
+116
New +$6.69K ﹤0.01% 2601

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northwestern Mutual Wealth Management's APLS Position: Q2 2026 in Review

Northwestern Mutual Wealth Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 10,281 shares — an estimated $414K sold.

Northwestern Mutual Wealth Management first reported a position in APLS in Q1 2023 and held it in 11 quarters. The position peaked at $414K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Northwestern Mutual Wealth Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 10,281 Apellis Pharmaceuticals shares in Q2 2026, an estimated $414K.
  • Northwestern Mutual Wealth Management first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 11 quarters.
  • Northwestern Mutual Wealth Management's Apellis Pharmaceuticals position peaked at $414K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.